EA201591435A1 - Новая композиция соединения ацетаминофена без побочного эффекта на печень - Google Patents
Новая композиция соединения ацетаминофена без побочного эффекта на печеньInfo
- Publication number
- EA201591435A1 EA201591435A1 EA201591435A EA201591435A EA201591435A1 EA 201591435 A1 EA201591435 A1 EA 201591435A1 EA 201591435 A EA201591435 A EA 201591435A EA 201591435 A EA201591435 A EA 201591435A EA 201591435 A1 EA201591435 A1 EA 201591435A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- liver
- acetaminophen
- tween
- polyoxyethylene
- toxicity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Новая композиция соединения без побочных эффектов на печень и используемая для устранения токсичности, оказываемой на печень лекарственным средством ацетаминофеном (N-ацетил-пара-аминофенол). Композиция соединения содержит в своем составе: (а) фармацевтически эффективное количество ацетаминофена и (b) общеупотребительное безопасное и фармацевтически приемлемое вспомогательное вещество, которое можно комбинировать с одним или несколькими лекарственными средствами для снижения токсичности печеночного фермента CYP2E1 при метаболизме лекарства в печени. Соединение выбрано из следующей группы, включающей: Tween 20, микрокристаллическую целлюлозу, дикальцийфосфат, 23 лауриловый эфир полиоксиэтилена, сахарин, маннитол, простой алкиловый эфир полиоксиэтилена, сукралозу, пирролидон, натрия крахмала гликолят, акриловую синтетическую смолу S100, натриевую соль карбоксиметилцеллюлозы, полиоксипропилен полиоксиэтилена, ментол, гидроксипропилцеллюлозу с низкой степенью замещения, крахмал прежелатинизированный, гидратированные декстраты NF, лимонную кислоту, касторовое масло полиоксиэтилена, коллоидную двуокись кремния, сложный эфир алифатического ряда моностеарата полиэтиленгликоля, сорбиновую кислоту, лимонное масло, гидроксипропилцеллюлозу, сорбитол, ацесульфам калия, фталат гипромеллозы, моногидрат лактозы, мальтодекстрин, Бридж 58, Бридж 76, Tween 80, Tween 40, ПЭГ 400, ПЭГ 4000, ПЭГ 2000 и аналогичные соединения для снижения побочных эффектов, вызываемых токсичностью, оказываемой ацетаминофеном на печень.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2013/087049 WO2015070396A1 (zh) | 2013-11-13 | 2013-11-13 | 无肝副作用的对乙酰胺基酚新复方组合 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201591435A1 true EA201591435A1 (ru) | 2016-05-31 |
EA029454B1 EA029454B1 (ru) | 2018-03-30 |
Family
ID=53056618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591435A EA029454B1 (ru) | 2013-11-13 | 2013-11-13 | Новая композиция соединения ацетаминофена без побочного эффекта на печень |
Country Status (15)
Country | Link |
---|---|
US (3) | US10420737B2 (ru) |
EP (2) | EP3069733B1 (ru) |
JP (1) | JP2016520100A (ru) |
KR (2) | KR101881074B1 (ru) |
CN (2) | CN111904924A (ru) |
DK (1) | DK3069733T3 (ru) |
EA (1) | EA029454B1 (ru) |
ES (1) | ES2929945T3 (ru) |
HR (1) | HRP20221344T1 (ru) |
HU (1) | HUE060309T2 (ru) |
LT (1) | LT3069733T (ru) |
PL (1) | PL3069733T3 (ru) |
PT (1) | PT3069733T (ru) |
RS (1) | RS63704B1 (ru) |
WO (1) | WO2015070396A1 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111904924A (zh) * | 2013-11-13 | 2020-11-10 | 财团法人国际教育基金会 | 化合物降低对乙酰氨基酚引起的肝毒性的用途及复方组合 |
BR112018005905B1 (pt) * | 2015-09-24 | 2023-03-21 | Sinew Pharma Inc | Composto, composição farmacêutica, e, uso de um composto |
TWI711464B (zh) * | 2015-11-19 | 2020-12-01 | 欣耀生醫股份有限公司 | 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法 |
JP2021513548A (ja) * | 2018-02-14 | 2021-05-27 | シニュー・ファーマ・インコーポレイテッドSiNew Pharma Inc. | アセトアミノフェン(apap)によって引き起こされる毒性を予防、低減または根絶するための方法および組成物 |
JP6858729B2 (ja) * | 2018-05-25 | 2021-04-14 | ▲財▼▲団▼法人国防教育研究基金会National Defense Education And Research Foundation | 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成 |
EP3846815A4 (en) * | 2018-09-03 | 2022-05-04 | Jacob Biotech Ltd | PHARMACEUTICAL PREPARATIONS OF SEBACOYL-DINALBUPHINE AND ACETAMINOPHEN AND METHODS FOR PAIN MANAGEMENT |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5584166A (en) * | 1978-12-20 | 1980-06-25 | Lion Hamigaki Kk | Band for spongy medicine |
ZA837556B (en) * | 1982-11-15 | 1984-06-27 | Upjohn Co | Acetominophen and ibuprofen/flurbiprofen |
JPS62502194A (ja) * | 1985-03-18 | 1987-08-27 | プロダクト・リソ−シズ・インタ−ナショナル・インコ−ポレイテッド | エ−ロゾル発泡体 |
ATE62407T1 (de) * | 1985-08-26 | 1991-04-15 | Procter & Gamble | Geschmack abdeckende zusammensetzungen. |
JPH01190628A (ja) * | 1988-01-21 | 1989-07-31 | Sumitomo Pharmaceut Co Ltd | 持続性坐剤 |
FR2646773B1 (fr) * | 1989-05-12 | 1994-05-13 | Chauvin Sa Laboratoire | Composition pharmaceutique a base de paracetamol |
EP0527153B1 (en) * | 1990-04-04 | 1996-07-24 | Berwind Pharmaceutical Services, Inc. | Aqueous maltodextrin and cellulosic polymer film coatings |
DE69425453T2 (de) * | 1993-04-23 | 2001-04-12 | Novartis Ag, Basel | Wirkstoffabgabevorrichtung mit gesteuerter Freigabe |
US5733578A (en) * | 1995-11-15 | 1998-03-31 | Edward Mendell Co., Inc. | Directly compressible high load acetaminophen formulations |
CA2255838A1 (en) * | 1996-05-20 | 1997-11-27 | Richard C. Fuisz | Melatonin in combination with analgesics |
US5858997A (en) * | 1997-12-04 | 1999-01-12 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Method and composition for skin lightening |
US8524277B2 (en) * | 1998-03-06 | 2013-09-03 | Alza Corporation | Extended release dosage form |
ES2153786B1 (es) * | 1999-06-10 | 2001-10-16 | S A L V A T Lab Sa | Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis. |
FR2798289B1 (fr) * | 1999-09-15 | 2004-12-31 | Cll Pharma | Formes galeniques a delitement rapide en bouche et leur procede de preparation |
BR0014966A (pt) * | 1999-10-29 | 2002-07-02 | Fmc Corp | Composição de revestimento de pronta liberação, endurecìvel e comestìvel |
ES2174734B1 (es) * | 2000-11-03 | 2003-10-01 | Belmac S A Lab | Nueva formulacion galenica de paracetamol dispersable y soluble, procedimiento para su preparacion y aplicaciones. |
KR100892333B1 (ko) * | 2001-07-10 | 2009-04-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 0차, 0차-2상, 증가적 또는 감소적 약물 전달을 위한 약물전달 시스템 |
JP2004538309A (ja) * | 2001-07-31 | 2004-12-24 | ワイエス | 不快な味覚をマスキングするためのスクラロース調合物 |
US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
KR100522239B1 (ko) * | 2002-07-16 | 2005-10-18 | 주식회사 서울제약 | 아세트아미노펜을 함유하는 제어방출성의 경구용 제제 |
KR100507771B1 (ko) * | 2002-11-08 | 2005-08-17 | 한미약품 주식회사 | 난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법 |
AU2004275835B2 (en) * | 2003-09-26 | 2011-06-23 | Alza Corporation | Controlled release formulations exhibiting an ascending rate of release |
ATE544447T1 (de) * | 2003-09-26 | 2012-02-15 | Alza Corp | Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung |
GB0330255D0 (en) * | 2003-12-31 | 2004-02-04 | Vectura Ltd | Multiparticulate formulations for oral delivery |
WO2006129668A1 (ja) * | 2005-05-30 | 2006-12-07 | Meiji Seika Kaisha, Ltd. | 糖衣を施した丸剤 |
US20080085314A1 (en) * | 2005-07-29 | 2008-04-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
WO2007050631A2 (en) * | 2005-10-25 | 2007-05-03 | Cima Labs Inc. | Dosage form with coated active |
WO2007074472A2 (en) * | 2005-12-27 | 2007-07-05 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide |
US10022339B2 (en) * | 2006-04-21 | 2018-07-17 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
WO2009014534A1 (en) * | 2007-07-20 | 2009-01-29 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
CN102006867A (zh) * | 2008-01-03 | 2011-04-06 | 沃根哈德研究中心 | 含有扑热息痛和布洛芬的口服药物混悬剂 |
EP2249808A2 (en) * | 2008-01-11 | 2010-11-17 | Cipla Limited | Solid pharmaceutical dosage form |
CN102137671B (zh) * | 2008-07-23 | 2012-10-17 | 国防教育研究基金会 | 含异烟碱酰胺(isoniazid,INH)低副作用的新复方 |
EP2405898A2 (en) * | 2009-03-09 | 2012-01-18 | Council Of Scientific & Industrial Research | Sustained release composition of therapeutic agent |
JP2011046666A (ja) * | 2009-08-28 | 2011-03-10 | Lion Corp | 医薬組成物 |
CN101695498A (zh) * | 2009-10-26 | 2010-04-21 | 昆明理工大学 | 对乙酰氨基酚所致肝损伤保护药物及其应用 |
CA3065589C (en) * | 2010-06-03 | 2022-04-26 | Catalent Ontario Limited | Multi phase soft gel capsules, apparatus and method thereof |
WO2012075455A2 (en) * | 2010-12-02 | 2012-06-07 | Aptalis Pharmatech, Inc. | Rapidly dispersing granules, orally disintegrating tablets and methods |
WO2012142724A1 (zh) * | 2011-04-20 | 2012-10-26 | 国防教育研究基金会 | 无/低副作用的抗结核病药物复方 |
CN102988993B (zh) * | 2011-09-13 | 2017-03-15 | 广东九明制药有限公司 | 复方对乙酰氨基酚片主要辅料的筛选和组成及其制备方法 |
JP5828280B2 (ja) * | 2011-12-28 | 2015-12-02 | ライオン株式会社 | 錠剤及びその製造方法 |
ES2414557B1 (es) | 2012-01-16 | 2014-06-10 | Novocat Farma, S.A. | Composición acuosa de paracetamol para inyección |
CN102600119B (zh) * | 2012-02-07 | 2013-03-27 | 海南卫康制药(潜山)有限公司 | 一种小儿对乙酰氨基酚组合物 |
CN103110629B (zh) * | 2013-02-19 | 2014-03-19 | 青岛正大海尔制药有限公司 | 复方酚麻美敏滴丸及其制备方法 |
CN111904924A (zh) * | 2013-11-13 | 2020-11-10 | 财团法人国际教育基金会 | 化合物降低对乙酰氨基酚引起的肝毒性的用途及复方组合 |
BR112018005905B1 (pt) * | 2015-09-24 | 2023-03-21 | Sinew Pharma Inc | Composto, composição farmacêutica, e, uso de um composto |
JP2021513548A (ja) * | 2018-02-14 | 2021-05-27 | シニュー・ファーマ・インコーポレイテッドSiNew Pharma Inc. | アセトアミノフェン(apap)によって引き起こされる毒性を予防、低減または根絶するための方法および組成物 |
-
2013
- 2013-11-13 CN CN202010418123.2A patent/CN111904924A/zh active Pending
- 2013-11-13 WO PCT/CN2013/087049 patent/WO2015070396A1/zh active Application Filing
- 2013-11-13 PT PT138976329T patent/PT3069733T/pt unknown
- 2013-11-13 EP EP13897632.9A patent/EP3069733B1/en active Active
- 2013-11-13 EP EP22183582.0A patent/EP4173619A3/en active Pending
- 2013-11-13 KR KR1020157023533A patent/KR101881074B1/ko active IP Right Grant
- 2013-11-13 JP JP2016515604A patent/JP2016520100A/ja active Pending
- 2013-11-13 US US14/441,317 patent/US10420737B2/en active Active
- 2013-11-13 RS RS20221004A patent/RS63704B1/sr unknown
- 2013-11-13 DK DK13897632.9T patent/DK3069733T3/da active
- 2013-11-13 LT LTEPPCT/CN2013/087049T patent/LT3069733T/lt unknown
- 2013-11-13 ES ES13897632T patent/ES2929945T3/es active Active
- 2013-11-13 HU HUE13897632A patent/HUE060309T2/hu unknown
- 2013-11-13 KR KR1020177019405A patent/KR102017550B1/ko active IP Right Grant
- 2013-11-13 CN CN201380058666.6A patent/CN105188756B/zh active Active
- 2013-11-13 HR HRP20221344TT patent/HRP20221344T1/hr unknown
- 2013-11-13 EA EA201591435A patent/EA029454B1/ru unknown
- 2013-11-13 PL PL13897632.9T patent/PL3069733T3/pl unknown
-
2019
- 2019-05-14 US US16/411,861 patent/US11534416B2/en active Active
-
2022
- 2022-11-23 US US17/993,183 patent/US20230082397A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2016520100A (ja) | 2016-07-11 |
CN111904924A (zh) | 2020-11-10 |
EP4173619A2 (en) | 2023-05-03 |
PL3069733T3 (pl) | 2023-02-13 |
CN105188756A (zh) | 2015-12-23 |
CN105188756B (zh) | 2020-06-12 |
EP4173619A3 (en) | 2023-07-19 |
KR102017550B1 (ko) | 2019-09-03 |
LT3069733T (lt) | 2022-11-25 |
EP3069733B1 (en) | 2022-08-10 |
US20190262289A1 (en) | 2019-08-29 |
ES2929945T3 (es) | 2022-12-05 |
US10420737B2 (en) | 2019-09-24 |
EA029454B1 (ru) | 2018-03-30 |
DK3069733T3 (da) | 2022-11-14 |
KR20170085607A (ko) | 2017-07-24 |
RS63704B1 (sr) | 2022-11-30 |
KR20150115846A (ko) | 2015-10-14 |
WO2015070396A1 (zh) | 2015-05-21 |
US20170172950A1 (en) | 2017-06-22 |
US20230082397A1 (en) | 2023-03-16 |
US11534416B2 (en) | 2022-12-27 |
HRP20221344T1 (hr) | 2022-12-23 |
HUE060309T2 (hu) | 2023-02-28 |
KR101881074B1 (ko) | 2018-08-17 |
PT3069733T (pt) | 2022-11-09 |
EP3069733A4 (en) | 2017-08-23 |
EP3069733A1 (en) | 2016-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591435A1 (ru) | Новая композиция соединения ацетаминофена без побочного эффекта на печень | |
HRP20180591T1 (hr) | Inhibitori kinaze serina ili treonina | |
EA201300989A1 (ru) | Водная фармацевтическая композиция тапентадола для перорального введения | |
NI201600098A (es) | Composiciones farmacéuticas que comprenden azd9291 | |
EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
RS53209B (en) | PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR | |
CO6341565A2 (es) | Inhibidores macrociclicos de serina proteasas de hepatitis c | |
ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
UA108363C2 (uk) | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
EA201590449A1 (ru) | Перорально вводимая лекарственная композиция | |
EA201391758A1 (ru) | Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты | |
NO341573B1 (no) | Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen | |
MY146988A (en) | Fexofenadine suspension formulation | |
EA201300539A1 (ru) | Твердая композиция для приема внутрь (варианты), способ терапевтической или нетерапевтической профилактики желудочно-кишечных расстройств или поддержания здорового состояния желудочно-кишечного тракта с ее помощью (варианты) и упаковка, ее содержащая | |
NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
EA201500245A1 (ru) | Твердый фармацевтический препарат, который содержит левотироксин | |
UY37550A (es) | Nueva formulación que comprende un derivado de bencimidazol | |
AR083393A1 (es) | Composicion farmaceutica liquida para el tratamiento y prevencion del dolor | |
BR112015013223A2 (pt) | composição farmacêutica | |
MX2015006011A (es) | Pastilla medicinal a base de ibuprofeno sodico dihidratado. | |
MX370184B (es) | Composición farmacéutica que comprende fingolimod. | |
RU2015115159A (ru) | Лечебно-профилактическая композиция для ухода за полостью рта гематоонкологических больных | |
ATE534382T1 (de) | Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon | |
EA201290378A1 (ru) | Композиции, содержащие нестероидные противовоспалительные лекарственные средства | |
AR089710A1 (es) | Composiciones farmaceuticas estabilizadas de un inhibidor del virus de hepatitis c |